托拉塞米与呋塞米对比治疗慢性心力衰竭的疗效观察

Clinical Effect Comparison of Torasemide and Furisemide in Treating Chronic Heart Failure

目的探究托拉塞米与呋塞米对比治疗慢性心力衰竭(chronic-heart-failuye,CHF)的临床疗效。方法选择2014年1月至2014年12月期间我院收治的84例慢性心力衰竭患者,随机数字表法平均分为托拉塞米组和呋塞米组各42例,观察对比两组临床疗效。结果疗程结束后,托拉塞米组临床总有效率为92.9%,明显高于呋塞米组的81.0%,P<0.05。托拉塞米组的24 h尿量和血钾水平,均明显多于呋塞米组,P<0.05。托拉塞米组药物不良反应发生率为11.9%,明显低于呋塞米组的28.6%,组间比较差别无统计学意义(χ2=3.614,P=0.057)。结论托拉塞米用于CHF治疗,改善心衰病情,并可增加排尿量,降低体质量,保钾排钠效果好,且用药安全性高。

Objective To explore the clinical effect difference of Torasemide and Furosemide in treating chronic heart failure. Methods 84 patients in our hospital who suffered from chronic heart failure from January to December in 2014 were randomly selected and divided into two groups, Torasemide group and Furosemide group, with 42 patients in each group. The clinical effects of the two groups were compared. Results After the course of treatment, the total effective rate of Torasemide group was 92. 9%, apparently higher than that of Furosemide group, which was 81.0% （P 〈0. 05）. 24h urinary volume and Potassium levels of Torasemide group were obviously higher than those of Furosemide group （ P 〈 0.05 ）. The incidence rate of adverse drug reactions of Torasemide group was 11.9%, apparently lower than that of Furosemide group, which was 28.6% （ P 〈 0. 05 ）. Conclusion Torasemide can not only improve the heart failure, increase urinary output and reduce body mass, but also it has a great medical effect on maintaining potassi- um and getting rid of sodium. Besides, it has high drug security.